Goodwin Biotechnology, Inc., a biological contract manufacturing organization, provides a range of mammalian cell culture development and manufacturing services. The company focuses on the research, development, manufacture, and validation of cytotoxic antibody drug conjugates, radioimmunoconjugates, monoclonal antibodies, recombinant proteins, vaccines, and other biologic drug conjugates for early and late stage clinical trials. It offers cell culture development, purification, bioconjugation, biosimilars, process development and cGMP manufacturing, and aseptic filling and finishing services. The company also provides support services, such as assay development, quality control and assurance, regulatory support, drug master files, project management, translational medicine, and consulting services. It serves academic institutions, biotechnology startups, and multinational biopharmaceutical companies in North America, Europe, and Asia. The company was founded in 1992 and is based in Plantation, Florida. Goodwin Biotechnology, Inc. operates as a subsidiary of Wallace Pharmaceuticals Ltd.